NSE: APLLTD | BSE: 533573

Slowing Down Stock

Download real time

716.15 -13.45 (-1.84%)

New 52W Low today

61,905 NSE+BSE Volume

NSE 27 Feb, 2026 1:23 PM (IST)

14,076.9

Market Cap

High in industry

Beta 1Year

Very Low volatility

US FDA Approval

Alembic Pharma gets US FDA nod for seizure treatment drug, with a market size of $27 million See details

Alembic Pharmaceuticals Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for APLLTD, BSE:533573 Alembic Pharmaceuticals Ltd.

Search Inside the pdf :

Alembic Pharmaceuticals Ltd.

05 Feb 2026

716.15

-1.84%

Ex-US and Animal Health perform, while DF and US lag

Neutral: Alembic Pharmaceuticals Ltd.

Target

Motilal Oswal

Alembic Pharma (ALPM) exhibited in-line revenue with a slight miss on EBITDA/PAT for the quarter. While ex-US export growth was strong for the quarter, it was offset by moderate YoY growth in domestic formulation (DF) and US sales.

Alembic Pharma has lost -23.53% in the last 6 Months

Alembic Pharmaceuticals Ltd.

05 Nov 2025

716.15

-1.84%

Strong Q2FY26 performance driven by US generics, margin expansion, and broad-based growth momentum

Buy: Alembic Pharmaceuticals Ltd.

Recommendation Target

Deven Choksey

Alembic Pharma is expected to maintain steady growth momentum supported by its expanding complex generics portfolio in the US, sustained traction in Ex-US markets, and a gradual recovery in the domestic formulations business.

Alembic Pharma has lost -21.71% in the last 3 Months

Alembic Pharmaceuticals Ltd.

05 Nov 2025

716.15

-1.84%

Export drives the show; India outlook cloudy

Hold: Alembic Pharmaceuticals Ltd.

Target

ICICI Securities Limited

Alembic Pharma’s (Alembic) Q2FY26 result beat our expectations – led by formulations exports (up 25.1% YoY) while India continued to grow at a modest pace (4.9% in Q2FY26).

Alembic Pharma has lost -23.53% in the last 6 Months

Alembic Pharmaceuticals Ltd.

05 Nov 2025

716.15

-1.84%

Alembic Pharma (BUY): All-round beat, US branded product entry to drive margins

Buy: Alembic Pharmaceuticals Ltd.

Target

BOB Capital Markets Ltd.

Sales/EBITDA /PAT reported 7%/4%/8% above our estimates. EBITDA margin was marginally 50 bps below our estimates

Alembic Pharma has lost -21.71% in the last 3 Months

Alembic Pharmaceuticals Ltd.

05 Nov 2025

716.15

-1.84%

Strong Q2FY26 performance driven by US generics, margin expansion, and broad-based growth momentum

Buy: Alembic Pharmaceuticals Ltd.

Recommendation Target

Deven Choksey

Alembic Pharma has lost -23.53% in the last 6 Months

Alembic Pharmaceuticals Ltd.

12 Aug 2025

716.15

-1.84%

Steady Q1FY26 performance with positive FY26E outlook

Accumulate: Alembic Pharmaceuticals Ltd.

Deven Choksey

We maintain a positive FY26E outlook, expecting sustained double-digit growth across US, Ex-US, and RoW businesses. Growth across regions will be majorly driven by a healthy US pipeline, strategic expansion in RoW, and improved execution across India.

Alembic Pharma has lost -23.53% in the last 6 Months

Alembic Pharmaceuticals Ltd.

06 Aug 2025

716.15

-1.84%

ERRATA: Alembic Pharma (BUY): Strong product mix to drive margins

Buy: Alembic Pharmaceuticals Ltd.

Target

BOB Capital Markets Ltd.

Earnings reported in-line where sales/EBITDA/PAT were -2.6/3.4%/-0.7% above estimates. EBITDA margin was 90 bps above estimates

Alembic Pharmaceuticals Ltd. is trading below all available SMAs

Alembic Pharmaceuticals Ltd.

06 Aug 2025

716.15

-1.84%

Turnaround in US growth; tepid traction in India

Hold: Alembic Pharmaceuticals Ltd.

Target

ICICI Securities Limited

Alembic Pharma’s (Alembic) Q1FY26 result was in line with our expectations. Revenue growth was mainly driven by US (13% YoY) and ex-US international business (21% YoY). India growth was tepid at 4.7% YoY due to challenges in specialty portfolio (up 1% YoY) and slowdown in acute market.

Alembic Pharma has lost -23.53% in the last 6 Months

Alembic Pharmaceuticals Ltd.

05 Aug 2025

716.15

-1.84%

Export strength offsets muted DF/API show

Neutral: Alembic Pharmaceuticals Ltd.

Target

Motilal Oswal

Alembic Pharma (ALPM) delivered a largely in-line performance for 1QFY26. Superior execution in the export market led to YoY growth in revenue/EBITDA/PAT for the quarter.